United States Antimony Corporation
UAMYUnited States Antimony Corporation's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.
The price is between stages. Underneath, the last four quarters read mixed. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
United States Antimony Corporation trades at $6.1, between stages. That is −24.4% against its own 200-day average. It sits at 23% of a 52-week range of $4 to $12. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (11 weeks and counting).
Today the stock is between stages. At $6.1 it trades −24.4% versus its 200-day average and sits at 23% of its 52-week range ($4–$12).
Against the market, two honest reads. Cumulative: over the last 1.1 years the stock moved +125% while the S&P 500 moved +24% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (11 weeks and counting; last ahead the week of 2026-05-22) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
P/E does not price United States Antimony Corporation — earnings are negative, so there is no multiple to rank against its own history. The revenue and margin lines below are where a turn, when it comes, would show first. On sales the market values United States Antimony Corporation at 25.0× its FY25 revenue of $0.0 B.
With earnings negative, P/E does not price — there is no multiple to rank against its own history. The revenue and margin lines below are where the turn, when it comes, will show first.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
United States Antimony Corporation reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 12 quarters across 1 curve, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +300.0% | +58.7% | — | — |
| Stock price | +106.8% | — | — | — |
4-Factor Sector Score
33.3/100 — rank 11 of 30 in Other Industrial Metals & Mining · 58% evidence confidence
United States Antimony Corporation scores 33.3 out of 100 against the 30 companies it is compared with in Other Industrial Metals & Mining, ranking 11. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 13.4 + 5.5 + 9.1 + 5.3 = 33.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
United States Antimony Corporation reported $0.0 B of revenue in the Mar 26 quarter, +0.0% year on year. Over 4 years it has compounded at 41.4% a year. The last full year, FY25, came in at $0.0 B. The last four reported quarters add to $0.0 B.
FY25 revenue came in at $0.0 B (+300.0% on the year), capping 4 years at 41.4% compound. The latest quarter (Mar 26) printed $0.0 B, +0.0% year on year.
Pace check: the last four quarters averaged +0.0% growth against the decade's 41.4% — the current year is running slower than its own long-run rate.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
United States Antimony Corporation's operating margin is −100.0% in the Mar 26 quarter, −100.0 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −100.0% to 0.0%. The current quarter sits inside that band.
The latest quarter's operating margin is −100.0%, −100.0 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −100.0%–0.0%.
🚨 Why the margin moved: operating margin went −100.0 pp year on year while gross margin went +0.0 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
United States Antimony Corporation posted a net loss of $0.01 B in the Mar 26 quarter. Full-year FY25 profit was $0.0 B. That loss is 100.0% of the quarter's revenue. The same quarter a year earlier earned $0.0 B. 1 of the last 12 reported quarters were loss-making.
Mar 26 profit was $−0.0 B, null year on year. On the full year, FY25 printed $0.0 B (null).
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
United States Antimony Corporation's cash-flow history is too thin to judge how much reported profit converts into cash. In FY25 that was $−0.0 B of operating cash against $0.0 B of profit. After $0.0 B of capital spending, $−0.0 B was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.
FY25: operating cash of $−0.0 B against reported profit of $0.0 B, leaving free cash of $−0.0 B after $0.0 B of capital spending.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
United States Antimony Corporation does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
United States Antimony Corporation earns a ROE of 0% in FY25. That is up from a trough of −33% in FY23. Return on invested capital clears the cost of that capital by −21.0 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 0.0% net margin on 0.27× asset turns.
FY25 ROE is 0%, recovered from a FY23 trough of −33% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY25): 0.0% net margin × 0.27× asset turns × 1.07× balance-sheet leverage ≈ 0.0% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: −14.5% − 6.5% = a −21.0 pp spread. The 6.5% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Dividend
United States Antimony Corporation pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
United States Antimony Corporation does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
United States Antimony Corporation carries total debt of $0.0 B against shareholder equity of $0.1 B as of Mar 26, a debt-to-equity of 0.00 — effectively unlevered. On the annual view that ratio went from 0.00 in FY21 to 0.00 in FY25. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of $0.0 B against shareholder equity of $0.1 B — a debt-to-equity of 0.00. On the annual view, debt-to-equity went from 0.00 (FY21) to 0.00 (FY25). The returns on this page are earned, not borrowed.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
23.7% of United States Antimony Corporation's tradable float is currently sold short — a large bloc is positioned against it. At typical trading volumes those positions would take about 4.7 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 23.7% of the float is sold short, and at typical trading volumes it would take about 4.7 days to buy those positions back. A large bloc is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
United States Antimony Corporation: the Z-score reads 28.92. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 28.92 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 28.92.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Santacruz Silver Mining Ltd.SCZM | 65.6/100Favorable setup81% evidence | ASLEEP | 23.7/35 Revenue 28% · PAT 46.3% · OPM change -5.3 pp 83% evidence | 19.6/25 ROCE 30.1% · OPM 26.6% 76% evidence | 15.2/20 P/E 13× · PEG 0.36 65% evidence | 7.1/20 RS sector -12.6% · RS bench -18.7% · 1Y 78.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 23.7 + 19.6 + 15.2 + 7.1 = 65.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Teck Resources LimitedTECK | 65.4/100Thin evidence · provisional58% evidence | ASLEEP | 22.2/35 Revenue — · PAT — · OPM change 19.3 pp 45% evidence | 14.9/25 ROCE 3.9% · OPM 41.2% 76% evidence | 9.8/20 P/E 16.6× · PEG — 15% evidence | 18.5/20 RS sector 22.4% · RS bench 14.9% · 1Y 96%3 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 14.9 + 9.8 + 18.5 = 65.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 3Nexa Resources S.A.NEXA | 61.6/100Thin evidence · provisional58% evidence | FADING | 20.8/35 Revenue 16% · PAT — · OPM change 14.8 pp 62% evidence | 13.4/25 ROCE 5.5% · OPM 23.4% 76% evidence | 10.7/20 P/E 6.7× · PEG — 15% evidence | 16.7/20 RS sector 33.8% · RS bench 21.2% · 1Y 177.2%6 of 12 weeks ahead 70% evidence |
| Exact sum: 20.8 + 13.4 + 10.7 + 16.7 = 61.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4Almonty Industries Inc.ALM | 58.2/100Thin evidence · provisional55% evidence | ASLEEP | 24.2/35 Revenue 72.4% · PAT — · OPM change 87.5 pp 62% evidence | 10.3/25 ROCE 1% · OPM 14% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 13.7/20 RS sector 11.5% · RS bench -0.9% · 1Y 222.3%1 of 12 weeks ahead 70% evidence |
| Exact sum: 24.2 + 10.3 + 10 + 13.7 = 58.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Vale S.A.VALE | 56.9/100Thin evidence · provisional58% evidence | ASLEEP | 20.1/35 Revenue — · PAT — · OPM change 3.5 pp 45% evidence | 15.0/25 ROCE 5.5% · OPM 25.7% 76% evidence | 9.4/20 P/E 30.7× · PEG — 15% evidence | 12.4/20 RS sector 1.4% · RS bench -4.7% · 1Y 45.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 20.1 + 15 + 9.4 + 12.4 = 56.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6Materion CorporationMTRN | 55.9/100Thin evidence · provisional58% evidence | LEADER | 15.2/35 Revenue — · PAT — · OPM change -3.4 pp 45% evidence | 12.1/25 ROCE 1.8% · OPM 5.1% 76% evidence | 9.0/20 P/E 40.7× · PEG — 15% evidence | 19.6/20 RS sector 35.4% · RS bench 27.1% · 1Y 113.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 15.2 + 12.1 + 9 + 19.6 = 55.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7Americas Gold and Silver CorporationUSAS | 55.5/100Thin evidence · provisional55% evidence | ASLEEP | 24.6/35 Revenue 58.3% · PAT — · OPM change 87.3 pp 62% evidence | 15.0/25 ROCE 11.6% · OPM 39.9% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 5.9/20 RS sector -16.8% · RS bench -24.1% · 1Y 60.8%0 of 12 weeks ahead 70% evidence |
| Exact sum: 24.6 + 15 + 10 + 5.9 = 55.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8Compass Minerals International, Inc.CMP | 55.1/100Thin evidence · provisional58% evidence | FADING | 19.0/35 Revenue 6.4% · PAT — · OPM change 13 pp 62% evidence | 11.5/25 ROCE 4.8% · OPM 12.4% 76% evidence | 8.5/20 P/E 155.7× · PEG — 15% evidence | 16.1/20 RS sector 21.9% · RS bench 15.2% · 1Y 39%11 of 12 weeks ahead 70% evidence |
| Exact sum: 19 + 11.5 + 8.5 + 16.1 = 55.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Ferroglobe PLCGSM | 42.0/100Thin evidence · provisional58% evidence | BASING | 18.7/35 Revenue -11.8% · PAT — · OPM change 15.9 pp 62% evidence | 9.1/25 ROCE -0.8% · OPM -2.2% 76% evidence | 9.3/20 P/E 31.7× · PEG — 15% evidence | 4.9/20 RS sector -26.9% · RS bench -29.4% · 1Y -15.6%0 of 12 weeks ahead 70% evidence |
| Exact sum: 18.7 + 9.1 + 9.3 + 4.9 = 42 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10MP Materials Corp.MP | 35.0/100Mixed-negative evidence64% evidence | ASLEEP | 14.0/35 Revenue 18.1% · PAT — · OPM change -16 pp 62% evidence | 8.1/25 ROCE -2.3% · OPM -73.2% 76% evidence | 8.7/20 P/E 141.8× · PEG — 15% evidence | 4.2/20 RS sector -28.1% · RS bench -29.6% · 1Y -36.1%2 of 12 weeks ahead 100% evidence |
| Exact sum: 14 + 8.1 + 8.7 + 4.2 = 35 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11United States Antimony Corporationthis pageUAMY | 33.3/100Thin evidence · provisional58% evidence | ASLEEP | 13.4/35 Revenue 100% · PAT — · OPM change -115.9 pp 62% evidence | 5.5/25 ROCE -8.9% · OPM -110.8% 76% evidence | 9.1/20 P/E 36.8× · PEG — 15% evidence | 5.3/20 RS sector -23% · RS bench -28.1% · 1Y 68.1%1 of 12 weeks ahead 70% evidence |
| Exact sum: 13.4 + 5.5 + 9.1 + 5.3 = 33.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12BHP Group LimitedBHP | 60.7/100Thin evidence · provisional38% evidence | ASLEEP | 17.9/35 Revenue — · PAT — · OPM change — 9% evidence | 14.2/25 ROCE 6.5% · OPM — 46% evidence | 9.9/20 P/E 15× · PEG — 15% evidence | 18.7/20 RS sector 21.1% · RS bench 14.4% · 1Y 65.5%3 of 12 weeks ahead 100% evidence |
| Exact sum: 17.9 + 14.2 + 9.9 + 18.7 = 60.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Rio Tinto GroupRIO | 58.8/100Thin evidence · provisional43% evidence | ASLEEP | 17.7/35 Revenue — · PAT — · OPM change — 12% evidence | 13.8/25 ROCE 4.1% · OPM — 61% evidence | 10.4/20 P/E 12.9× · PEG — 15% evidence | 16.9/20 RS sector 12.1% · RS bench 5.3% · 1Y 60.1%2 of 12 weeks ahead 100% evidence |
| Exact sum: 17.7 + 13.8 + 10.4 + 16.9 = 58.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Evolution Metals & Technologies Corp.EMAT | 52.8/100Thin evidence · provisional34% evidence | ASLEEP | 17.9/35 Revenue — · PAT — · OPM change — 4% evidence | 14.8/25 ROCE 276.6% · OPM -332.9% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.1/20 RS sector 0.1% · RS bench -9.1% · 1Y -73.6%0 of 12 weeks ahead 70% evidence |
| Exact sum: 17.9 + 14.8 + 10 + 10.1 = 52.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15Sigma Lithium CorporationSGML | 52.4/100Thin evidence · provisional50% evidence | ASLEEP | 21.2/35 Revenue — · PAT — · OPM change 18.4 pp 39% evidence | 14.1/25 ROCE 8% · OPM 32.6% 76% evidence | 8.8/20 P/E 109.4× · PEG — 15% evidence | 8.3/20 RS sector -3.6% · RS bench -12.5% · 1Y 104%4 of 12 weeks ahead 70% evidence |
| Exact sum: 21.2 + 14.1 + 8.8 + 8.3 = 52.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16Elevra Lithium LimitedELVR | 50.7/100Thin evidence · provisional15% evidence | ASLEEP | 16.5/35 Revenue — · PAT — · OPM change — 9% evidence | 14.2/25 ROCE 12.6% · OPM — 46% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —5 of 12 weeks ahead 0% evidence |
| Exact sum: 16.5 + 14.2 + 10 + 10 = 50.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Lithium Argentina AGLAR | 50.1/100Thin evidence · provisional44% evidence | ASLEEP | 18.3/35 Revenue — · PAT — · OPM change — 33% evidence | 10.8/25 ROCE 1.2% · OPM — 61% evidence | 11.3/20 P/E 0.4× · PEG — 15% evidence | 9.7/20 RS sector -0.4% · RS bench -9.6% · 1Y 128.5%6 of 12 weeks ahead 70% evidence |
| Exact sum: 18.3 + 10.8 + 11.3 + 9.7 = 50.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18NioCorp Developments Ltd.NB | 47.4/100Thin evidence · provisional44% evidence | ASLEEP | 21.1/35 Revenue — · PAT — · OPM change — 33% evidence | 8.7/25 ROCE -3.1% · OPM — 61% evidence | 11.0/20 P/E 3.6× · PEG — 15% evidence | 6.6/20 RS sector -15.4% · RS bench -18.4% · 1Y 9.5%0 of 12 weeks ahead 70% evidence |
| Exact sum: 21.1 + 8.7 + 11 + 6.6 = 47.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Skeena Resources LimitedSKE | 45.2/100Thin evidence · provisional47% evidence | ASLEEP | 15.1/35 Revenue — · PAT — · OPM change — 33% evidence | 6.7/25 ROCE -5% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 13.4/20 RS sector 4.2% · RS bench -3.6% · 1Y 76.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.1 + 6.7 + 10 + 13.4 = 45.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Blue Moon Metals Inc.BMM | 44.5/100Thin evidence · provisional44% evidence | ASLEEP | 12.2/35 Revenue — · PAT — · OPM change — 33% evidence | 5.7/25 ROCE -15.7% · OPM — 61% evidence | 11.2/20 P/E 2.7× · PEG — 15% evidence | 15.4/20 RS sector 20.4% · RS bench 9.2% · 1Y 113.5%5 of 12 weeks ahead 70% evidence |
| Exact sum: 12.2 + 5.7 + 11.2 + 15.4 = 44.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21IperionX LimitedIPX | 42.1/100Thin evidence · provisional41% evidence | ASLEEP | 19.8/35 Revenue — · PAT — · OPM change — 33% evidence | 9.0/25 ROCE 0% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.3/20 RS sector -43% · RS bench -44.2% · 1Y -37.2%1 of 12 weeks ahead 70% evidence |
| Exact sum: 19.8 + 9 + 10 + 3.3 = 42.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Critical Metals Corp.CRML | 41.3/100Thin evidence · provisional37% evidence | ASLEEP | 17.9/35 Revenue — · PAT — · OPM change — 24% evidence | 7.6/25 ROCE -14.6% · OPM — 46% evidence | 11.5/20 P/E 0× · PEG — 15% evidence | 4.3/20 RS sector -33.9% · RS bench -38.4% · 1Y 46.4%3 of 12 weeks ahead 70% evidence |
| Exact sum: 17.9 + 7.6 + 11.5 + 4.3 = 41.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23TMC the metals company Inc.TMC | 41.2/100Thin evidence · provisional50% evidence | ASLEEP | 20.3/35 Revenue — · PAT — · OPM change — 33% evidence | 5.4/25 ROCE -49.4% · OPM — 61% evidence | 10.9/20 P/E 5.9× · PEG — 15% evidence | 4.6/20 RS sector -37% · RS bench -39.2% · 1Y -29.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 20.3 + 5.4 + 10.9 + 4.6 = 41.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 24Lithium Americas Corp.LAC | 39.8/100Thin evidence · provisional41% evidence | ASLEEP | 16.5/35 Revenue — · PAT — · OPM change — 33% evidence | 9.7/25 ROCE -0.6% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.6/20 RS sector -37.7% · RS bench -40.7% · 1Y 10.4%0 of 12 weeks ahead 70% evidence |
| Exact sum: 16.5 + 9.7 + 10 + 3.6 = 39.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25Trilogy Metals Inc.TMQ | 39.7/100Thin evidence · provisional41% evidence | ASLEEP | 14.9/35 Revenue — · PAT — · OPM change — 33% evidence | 8.3/25 ROCE -1.7% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 6.5/20 RS sector -14.5% · RS bench -20.8% · 1Y 126.3%0 of 12 weeks ahead 70% evidence |
| Exact sum: 14.9 + 8.3 + 10 + 6.5 = 39.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26REalloys Inc.ALOY | 39.6/100Thin evidence · provisional43% evidence | TURNING | 11.2/35 Revenue — · PAT — · OPM change -96.5 pp 39% evidence | 5.2/25 ROCE -155.8% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 13.2/20 RS sector 6.1% · RS bench -1.8% · 1Y 66.8%5 of 12 weeks ahead 70% evidence |
| Exact sum: 11.2 + 5.2 + 10 + 13.2 = 39.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27Vizsla Silver Corp.VZLA | 38.4/100Thin evidence · provisional41% evidence | BASING | 14.5/35 Revenue — · PAT — · OPM change — 33% evidence | 8.3/25 ROCE -2.4% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 5.6/20 RS sector -22.5% · RS bench -25% · 1Y 3.7%0 of 12 weeks ahead 70% evidence |
| Exact sum: 14.5 + 8.3 + 10 + 5.6 = 38.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 28Northern Dynasty Minerals Ltd.NAK | 37.8/100Thin evidence · provisional44% evidence | ASLEEP | 12.9/35 Revenue — · PAT — · OPM change — 33% evidence | 6.7/25 ROCE -12.4% · OPM — 61% evidence | 10.6/20 P/E 7.2× · PEG — 15% evidence | 7.6/20 RS sector -9.6% · RS bench -15.8% · 1Y 77.8%7 of 12 weeks ahead 70% evidence |
| Exact sum: 12.9 + 6.7 + 10.6 + 7.6 = 37.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29USA Rare Earth, Inc.USAR | 37.1/100Thin evidence · provisional45% evidence | ASLEEP | 17.0/35 Revenue — · PAT -1061% · OPM change — 7% evidence | 6.2/25 ROCE -3.4% · OPM -643.6% 76% evidence | 9.6/20 P/E 17× · PEG — 15% evidence | 4.3/20 RS sector -14.1% · RS bench -18.7% · 1Y 6.2%6 of 12 weeks ahead 100% evidence |
| Exact sum: 17 + 6.2 + 9.6 + 4.3 = 37.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 30Standard Lithium Ltd.SLI | 36.0/100Thin evidence · provisional50% evidence | ASLEEP | 17.0/35 Revenue — · PAT -127.6% · OPM change — 33% evidence | 8.9/25 ROCE -0.9% · OPM — 61% evidence | 10.1/20 P/E 13.2× · PEG — 15% evidence | 0.0/20 RS sector -44.4% · RS bench -47.2% · 1Y -22.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17 + 8.9 + 10.1 + 0 = 36 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is United States Antimony Corporation's stock price today?
United States Antimony Corporation trades at $6.1, +106.8% over the past year. The company is valued at $1.0 B. The stock sits at 23% of its 52-week range of $4–$12, −24.4% versus its 200-day average. Against the S&P 500 it has been behind on a trailing-13-week view for 11 weeks. — as of 5 August 2026.
What were United States Antimony Corporation's latest quarterly results?
United States Antimony Corporation reported revenue of $0.0 B and a net loss of $0.0 B for the Mar 26 quarter. Earnings per share were $−0.08. The operating margin was −100.0%, 100.0 pp lower than a year earlier. — as of 5 August 2026.
What is United States Antimony Corporation's revenue?
United States Antimony Corporation reported revenue of $0.0 B in the Mar 26 quarter, +0.0% year on year. For the full FY25 fiscal year, revenue was $0.0 B (+300.0%). Over the last 4 years revenue compounded at 41.4% a year. — as of 5 August 2026.
What is United States Antimony Corporation's profit?
United States Antimony Corporation earned $−0.0 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $0.0 B. The operating margin ran −100.0% in the latest quarter. — as of 5 August 2026.
What is United States Antimony Corporation's market cap?
United States Antimony Corporation's market capitalisation is $1.0 B at a stock price of $6.1. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
Does United States Antimony Corporation pay a dividend?
No — United States Antimony Corporation has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 5 August 2026.
How is United States Antimony Corporation performing?
United States Antimony Corporation's latest readings are below. Against the S&P 500 it has been behind on a trailing-13-week view for 11 weeks. This describes what the data did, not a rating. — as of 5 August 2026.
Is United States Antimony Corporation beating the market?
Not lately — on a trailing-13-week view United States Antimony Corporation is currently behind the S&P 500 (11 weeks and counting; last ahead the week of 2026-05-22), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 1.1 years the stock moved +125% against the S&P 500's +24% — ahead of the index over the full window. — as of 5 August 2026.
Will United States Antimony Corporation's stock price go up?
This page publishes no price forecast for United States Antimony Corporation. What it measures instead: the stock price is $6.1. Direction is not something this site claims to know. — as of 5 August 2026.
Is the market betting against United States Antimony Corporation?
Yes — short interest is 23.7% of United States Antimony Corporation's tradable float, about 4.7 days to cover at typical volumes. A crowded short: a large bloc is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
What is United States Antimony Corporation's capex?
United States Antimony Corporation spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 5 August 2026.
What is United States Antimony Corporation's cash flow?
United States Antimony Corporation generated $−0.0 B of operating cash flow in FY25 and $−0.0 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $0.0 B, so operating cash ran behind profit. — as of 5 August 2026.
How financially safe is United States Antimony Corporation?
On the balance sheet, the Z-score reads 28.92 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 5 August 2026.
Where is United States Antimony Corporation in its business cycle?
United States Antimony Corporation's FY25 operating margin was −25.0%, against a 5-year band of −100.0%–0.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran −100.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the United States Antimony Corporation story?
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is United States Antimony Corporation a stock worth studying right now?
This is not investment advice. The machine read: United States Antimony Corporation's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.